Getinge, a provider of products and solutions to hospitals life science institutions, has acquired US-based medical device company Verrix for an undisclosed sum.

Based in San Clemente, California, Verrix has developed a rapid biological indicator system for initial application in the operating room’s steam sterilisation workflow.

Verrix is said to use advanced technologies to protect patients from healthcare-associated infections.

Getinge surgical workflows president Stéphane Le Roy said: “There is a growing demand for biological indicators from healthcare institutions around the world, and what Verrix has developed in this field is truly impressive, setting new standards of speed and accuracy.

“We are looking forward to adding this new infection control technology to our customer offering.”

Using scientific expertise and establishing partnerships with healthcare professionals, Verrix focuses on the development of advanced solutions for sterility assurance, environmental monitoring, and infection control.

Originally discovered at NASA’s Jet Propulsion Laboratory, the foundational sterility assurance technology incorporates advanced optical physics, chemistry spectroscopy, and molecular biology.

Verrix CEO Sami El-Saden said: “We are excited to be part of the Getinge team. This transaction strategically secures our global market entry into the hospital sterility monitoring segment.

“We believe that Verrix’s EVA platform will also enable the development of future biological indicators to augment Getinge’s expertise and commercial offerings across the healthcare and life science segments.”

Outcome Capital acted as the exclusive strategic and financial advisor to Verrix.

With over 10,000 employees, Getinge provides products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science.